Market Cap : 411.76 M | Enterprise Value : 183.58 M | PE Ratio : At Loss | PB Ratio : 1.61 |
---|
NAS:ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Atara Biotherapeutics's Enterprise Value is $183.58 Mil. Atara Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $-252.09 Mil. Therefore, Atara Biotherapeutics's EV-to-FCF for today is -0.73.
The historical rank and industry rank for Atara Biotherapeutics's EV-to-FCF or its related term are showing as below:
During the past 10 years, the highest EV-to-FCF of Atara Biotherapeutics was -0.16. The lowest was -6.93. And the median was -4.53.
ATRA's EV-to-FCF is ranked worse thanEV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-19), Atara Biotherapeutics's stock price is $4.49. Atara Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.550. Therefore, Atara Biotherapeutics's PE Ratio for today is At Loss.
For the Biotechnology subindustry, Atara Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's EV-to-FCF falls into.
Atara Biotherapeutics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 183.581 | / | -252.086 | |
= | -0.73 |
Atara Biotherapeutics's current Enterprise Value is $183.58 Mil.
Atara Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-252.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Atara Biotherapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 4.49 | / | -2.550 | |
= | At Loss |
Atara Biotherapeutics's share price for today is $4.49.
Atara Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Atara Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Yarema Kristin | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Murugan Amar | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Dupont Jakob | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 |
Touchon Pascal | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Koppikar Utpal | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Mallik Ameet | director | C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102 |
Renaud Ronald C Jr | director | C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109 |
Seidenberg Beth C | director | |
Heiden William K | director | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Dobmeier Eric | director | C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021 |
Roncarolo Maria Grazia | director | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Gallagher Carol Giltner | director | C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 |
Fust Matthew K | director | C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 |
Baynes Roy D. | director | C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 |
Berger Dietmar | officer: Global Head of R&D | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
Other Sources
By Zacks 2021-08-09
By tipranks.com 2022-03-22
By Zacks 2021-05-04
By tipranks.com 2022-03-18
By Fool 2022-02-18
By tipranks.com 2022-04-04